Enlivex Therapeutics Ltd. (TLV:ENLV)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
354.20
+29.60 (9.12%)
Dec 4, 2025, 5:25 PM IDT
-17.34%
Market Cap 95.16M
Revenue (ttm) n/a
Net Income (ttm) -42.05M
Shares Out n/a
EPS (ttm) -1.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 146,457
Average Volume 179,182
Open 340.00
Previous Close 324.60
Day's Range 340.00 - 356.90
52-Week Range 295.00 - 682.90
Beta 1.48
RSI 53.18
Earnings Date Nov 28, 2025

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 71
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol ENLV
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.